EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism

Feifei Han, Haiping Wang, Li Wang, Limei Fan, Sibei Peng, Xiaoying Hou, Xiji Shu, Binlian Sun, Yuchen Liu

International Journal of Nanomedicine · 2025

DOI: 10.2147/ijn.s515107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Feifei Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, School of Medicine, Jianghan University, Wuhan, Hubei, 430056, People's Republic of China. Hauptthemen laut MEDLINE: Silybin, Sorafenib, Fatty Acids, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SilybinSorafenibFatty AcidsFatty LiverAnimalsHumansHep G2 CellsMiceLipid MetabolismMaleMice, Inbred C57BLLiverDrug Carriers

Stichwörter der Autor:innen

fatty acid metabolismmetabolic dysfunction-associated steatotic liver diseaseself-assembled carrier-free microparticlessilibininsorafenib

Substanzen

SilybinSorafenibFatty AcidsDrug Carriers

Autor:innen und Institutionen

  • Cancer Institute, School of Medicine, Jianghan University, Wuhan, Hubei, 430056, People's Republic of China.
  • Hubei Key Laboratory of Cognitive and Affective Disorders, Jianghan University, Wuhan, Hubei, 430056, People's Republic of China.

Zitieren

APA

Han, F., Wang, H., Wang, L., Fan, L., Peng, S., Hou, X., Shu, X., Sun, B., & Liu, Y. (2025). Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s515107

Vancouver

Han F, Wang H, Wang L, Fan L, Peng S, Hou X, et al. Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s515107

BibTeX
@article{Han2025,
  author = {Han, Feifei and Wang, Haiping and Wang, Li and Fan, Limei and Peng, Sibei and Hou, Xiaoying and Shu, Xiji and Sun, Binlian and Liu, Yuchen},
  title = {Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  doi = {10.2147/ijn.s515107}
}
Kostenlos starten →